Intellia Therapeutics 주식 (NASDAQ: NTLA)

에 대한 최신 뉴스 Intellia Therapeutics (NASDAQ:NTLA) 주식

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Equities

News

Markets

ETFs

ADPT

ARKG

ARKK

ILMN

NTLA

RXRX

캐시 우드가 이끄는 아크 인베스트는 금요일에 리커젼 파마슈티컬스(NASDAQ:RXRX), 일루미나(NASDAQ:ILMN), 인텔리아 테라퓨틱스(NASDAQ:NTLA), 클라우드플레어(NYSE:NET) 그리고 어댑티브 바이오테크놀로지스(NASDAQ:ADPT)의 주요 회사들에서 상당한 거래를 진행했다.

캐시 우드의 아크 인베스트, 인력의 4분의 1 이상을 해고한 인텔리아 테라퓨틱스에 투자

Biotech

Health Care

BEAM

CDNA

CRSP

TWST

VCYT

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.

캐시 우드, 바이오 분야에서 4천억 달러 기회 전망

CPRI

MNPR

TSLA

미국 주식 시장은 목요일에 혼조세를 보였다. 나스닥 종합지수는 130포인트 이상 상승한 반면, 다우존스 지수는 0.3% 하락하여 42,374.36으로 마감되었다. S&amp;P 500 지수도 0.2% 상승하여 5,809.86으로 마감했다.

목요일 주목받은 주식: 모노파 테라퓨틱스, 인텔리아 테라퓨틱스, 카프리, 웨스턴 디지털 및 테슬라

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

WIIM

KYMR

Kymera Therapeutics shares are trading higher. Stephens & Co. reiterated an Overweight rating on the stock.

The Securities and Exchange Commission on Tuesday announced the formation of a dedicated crypto task force, signaling a potential shift in its <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43096311/exclusive-trump-does-not-establish-bitcoin-reserve-crypto-friendly-policies-on-day-1-and-now">approach to regulating digital assets</a>.
Acting Chairman Mark Uyeda <a href="https://www.sec.gov/newsroom/press-releases/2025-30">launched</a> the initiative, appointing Commissioner Hester Peirce to lead the agency-wide effort.
The task force aims to develop a clear and comprehensive regulatory framework for the cryptocurrency industry, an area that has been marked by legal uncertainty and enforcement-driven regulations.
Richard Gabbert and Taylor Asher will serve as Chief of Staff and Chief Policy Advisor, respectively.
The SEC has faced criticism for its reactive enforcement strategy, which has led to confusion about which practices are legal, hindering innovation, and creating opportunities for fraud within the crypto industry. 
This new task force intends to address these issues by establishing clearer regulatory lines, creating practical paths to registration for crypto firms, and developing sensible disclosure requirements.
"I look forward to the efforts of Commissioner Peirce to lead regulatory policy on crypto, which involves multiple SEC divisions and offices," said Acting Chairman Uyeda, underscoring the task force&#8217;s broad scope and importance.
Commissioner Peirce, known for her <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43008666/sec-under-trump-administration-to-revise-crypto-policies-report">pro-crypto stance</a>, emphasized the need for public input in shaping the new regulatory landscape.
Also Read:<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43107902/bank-of-america-ceo-signals-crypto-payment-acceptance-pending-regulatory-green-light"> Bank Of America CEO Signals Crypto Payment Acceptance, Pending Regulatory Green Light</a>
&#8220;This undertaking will take time, patience, and much hard work,&#8221; stated Commissioner Peirce. 
&#8220;It will succeed only if the Task Force has input from a wide range of investors, industry participants, academics, and other interested parties. 
We look forward to working hand-in-hand with the public to foster a regulatory environment that protects investors, facilitates capital formation, fosters market integrity, and supports innovation."
The task force will operate within existing legal frameworks set by Congress, whilst also looking at how these frameworks could be adjusted.
This announcement comes following former President Donald Trump's <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43096311/exclusive-trump-does-not-establish-bitcoin-reserve-crypto-friendly-policies-on-day-1-and-now">vocal support for the cryptocurrency industry</a>.
Trump, who has positioned himself as an advocate for crypto, previously promised to bring about a more lenient regulatory environment for digital assets. 
Under the tenure of former chair Gary Gensler, the SEC has focused on enforcement actions, leading some to criticize their approach. 
The new task force plans to collaborate with other regulatory bodies, including the Commodity Futures Trading Commission, as well as <a href="https://www.benzinga.com/25/01/43086698/crypto-market-plunges-after-trumps-inaugural-speech-fails-to-mention-digital-assets">state and international agencies.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43105356/meme-coin-supercycle-dogecoin-trump-bonk-futures-etf-applications-filed">Meme Coin Supercycle? Dogecoin, Trump, Bonk Futures ETF Applications Filed</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

SEC Launches Crypto Task Force To Establish Clear Regulatory Framework

Needham analyst Laura Martin reiterated Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Buy and a <a target="_blank" href="https://www.benzinga.com/quote/AAPL/analyst-ratings" rel="noreferrer noopener">$260&nbsp;price target</a>.
Martin hosted a panel of well-known experts on Apple during the Needham Growth Conference.
Panelists curate some of the largest blogs, podcasts, and websites dedicated to Apple alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/25/01/43096797/huawei-wants-to-take-nvidias-place-in-ai-in-china-shifts-focus-to-inference-over-training" rel="noreferrer noopener">Huawei Wants To Take Nvidia&#8217;s Place In AI In China, Shifts Focus to Inference Over Training</a>
In one case, 50% of the investors who pay for his blog own a single stock, Apple.
Martin summarized her top 10 takeaways from the Apple panel.
The Apple experts expressed optimism about Vision Pro as an entry point into spatial computing. However, they mentioned concerns regarding its clunky design, slow product iteration, high price point, and lack of a straightforward &#8220;killer app&#8221; software.
Although the Apple experts recognized the company&#8217;s lag in AI investments compared to Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), they noted that Apple&#8217;s strength lies in integrating Generative AI tools and features into its ecosystem instead of pursuing &#8220;headline-grabbing&#8221; projects.
The Apple experts debated whether, post-Steve Jobs, the company has only succeeded with sustaining innovations (improving existing products) instead of creating entirely new markets, as Jobs did with the iPod and iPhone. They noted that new products like the Vision Pro have not been successful with consumers.
Apple&#8217;s 30% App Store commission is very controversial. While critics view it as monopolistic, these experts noted that Apple has begun adjusting its policies (like reducing fees for certain smaller developers to 15%).
While the iPhone remains Apple&#8217;s anchor product, the company is diversifying its offerings into services, wearables, and Vision Pro, which they argue adds diversification and growth opportunities away from the iPhone.
Martin noted that Apple is a single-product company with add-on products that generate revenue from existing iPhone users.
If the iPhone falls behind, none of the other products can stand alone. Hence, Apple is not a diversified portfolio company.
Although Apple&#8217;s market share is substantial in the US (&gt;50%), it is smaller in regions like Asia (12%) and Africa (6%).
They argued that growing Apple&#8217;s market share in these markets offers revenue growth upside.
Martin noted that U.S. ARPUs are typically 2-4 times higher than offshore revenue and users, so Apple must add 2-4 times more users offshore to equal one user in the U.S. economically.
The rollout of domestically produced chips (like Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) American-made A-series) highlights Apple&#8217;s effort to localize and de-risk its supply chain amid geopolitical and macroeconomic uncertainties.
They noted that if Apple is successful at diversifying its manufacturing dependence away from China, this would lower its risk and add to its valuation multiple.
Services continue to grow at double-digit rates, driven by Apple&#8217;s ability to upsell services like iCloud and Apple Music to its iPhone user base. This recurring revenue model complements hardware sales at higher margins.
These Apple experts cited key risks as concerns over global economic downturns, tariffs, and regulatory pressures from regions like the EU and China. These could negatively affect Apple&#8217;s profitability and operational efficiency in 2025.
These experts noted that no stock is more likely to be an investor&#8217;s ONLY stock. A significant portion of their subscribers allocate their entire portfolios to Apple, a single company. This indicates extreme loyalty and confidence in Apple&#8217;s long-term value generation by these investors.
Price Action: AAPL stock is down 3.7% at $221.36 at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42986042/apple-sees-market-share-decline-in-2024-as-chinese-smartphone-brands-surge-globally-idc" target="_blank" rel="noreferrer noopener">Apple Sees Market Share Decline in 2024 as Chinese Smartphone Brands Surge Globally: IDC</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

AAPL

AMZN

GOOG

GOOGL

Apple's iPhone Dependence Remains, But Services, Wearables Offer Growth Potential: Analyst

SOUN

SoundHound AI shares are trading higher after the company announced a collaboration with Rekor Systems to enhance police vehicles through hands-free AI integration.

Citigroup analyst Scott Gruber maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Buy and raises the price target from $50 to $54.

Citigroup Maintains Buy on Schlumberger, Raises Price Target to $54

Shares of SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) are trading higher Tuesday following <a href="https://www.benzinga.com/pressreleases/25/01/b43097323/rekor-systems-taps-soundhound-ai-to-revolutionize-emergency-vehicle-technology-with-first-of-its-k">the announcement of a collaboration</a> with Rekor Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>).
What To know: The partnership between SoundHound AI and Rekor Systems will integrate SoundHound&#8217;s voice AI with Rekor&#8217;s vehicle recognition software, Rekor Scout, to enhance emergency vehicle technology. The goal is to create hands-free solutions for law enforcement and first responders, enabling the use of systems like automatic license plate recognition (ALPR), sirens and in-car data terminals via voice commands.
The technology will deliver real-time, voice-enabled alerts for wanted vehicles, Amber Alerts and other high-priority notifications, improving situational awareness by replacing traditional audio cues with natural language.
Initially focused on police vehicles, the solution will expand to fire trucks and ambulances. It will integrate with Mobile Data Terminals (MDTs) to allow officers to query databases, log incidents and perform tasks hands-free. Rekor Scout will also utilize existing high-resolution cameras in emergency vehicles, removing the need for additional hardware.
SoundHound CEO Keyvan Mohajer called the collaboration transformative, citing its potential to enhance safety and reduce distractions for law enforcement. Rekor leadership potentially emphasized its global relevance and role in modernizing policing technology.
SOUN Price Action: Soundhound shares were up 15.4% at $15.74 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21133947/Screenshot-2025-01-21-at-13.39.27-1024x529.png" alt="" class="wp-image-743365" style="width:548px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21133947/Screenshot-2025-01-21-at-13.39.27-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21133947/Screenshot-2025-01-21-at-13.39.27-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21133947/Screenshot-2025-01-21-at-13.39.27-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21133947/Screenshot-2025-01-21-at-13.39.27.png 1516w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43108987/home-health-services-provider-brightspring-health-divests-community-living-business-for-850-million-to-focus-on-core-activities">BrightSpring Health Divests Community Living Business For $850 Million To Focus On Core Activities</a></li>
</ul>
Image Via Shutterstock.

Movers

REKR

Soundhound AI Shares Are On The Rise Today: What's Going On?

Citigroup analyst Roland Shu downgrades United Microelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>) from Buy to Sell.

Downgrades

Citigroup Downgrades United Microelectronics to Sell

Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>) is rallying following a first filing for <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43105356/meme-coin-supercycle-dogecoin-trump-bonk-futures-etf-applications-filed">a Bonk ETF</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>)</td>
<td>&nbsp;$0.00003417&nbsp;&nbsp;</td>
<td>$2.6 billion</td>
<td>+10.5%&nbsp;</td>
<td>+25%&nbsp;</td>
</tr>
<tr>
<td>OFFICIAL TRUMP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>)</td>
<td>&nbsp;$42.39</td>
<td>$8.5 billion</td>
<td>+6%</td>
<td>+552.5%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3832</td>
<td>$56.6 billion</td>
<td>+6.9%&nbsp;</td>
<td>+7.4%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Mayne noted that BONK's price action reflects a strong push into demand, predicting it is "attempting a big reclaim."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24Bonk&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Bonk</a> Weekly sweep into demand. Now attempting a big reclaim. <a href="https://t.co/pgDlI2r0UV">pic.twitter.com/pgDlI2r0UV</a>
&mdash; Mayne (@Tradermayne) <a href="https://twitter.com/Tradermayne/status/1881736086948589621?ref_src=twsrc%5Etfw">January 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Unipcs, known as the &#8220;BONK Guy,&#8221; elaborated on BONK's unique positioning within the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) ecosystem. 
He argued that if Solana leads this cycle, BONK will naturally emerge as its primary meme coin. 
Factors like early ETF adoption, broad retail accessibility, and a strong low-unit bias position BONK for growth. 
Major exchanges like Robinhood, Coinbase, and Upbit already list the coin.
Unipcs further <a href="https://x.com/theunipcs/status/1881721798548492503">emphasized</a> that avoiding BONK exposure could result in a missed opportunity, given its potential for substantial returns.
Unipcs also <a href="https://x.com/theunipcs/status/1881729360731709813">highlighted</a> the explosive developments in the meme coin market within 24 hours of Donald Trump's inauguration. 
These include ETF filings, the formation of the Department of Government Efficiency (D.O.G.E), and the launch of an official website featuring Dogecoin's logo, signaling a new era for meme coins.
Statistics: BONK's valuation surged, placing it among the top 50 cryptocurrencies by market cap. 
Data from Coinglass shows that BONK's open interest spiked 17.8% in a day to $19.8 million, signaling increased trader activity and confidence.
Community News: Excitement around Trump's inauguration saw REXShares and Osprey filing for a series of crypto ETFs, including BONK, DOGE and TRUMP, amplifying optimism around BONK's future potential.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43066083/sol-has-a-50-of-flipping-ethereum-bonk-to-become-the-shiba-inu-of-solana-trader-posits">SOL Has A 50% Chance Of Flipping Ethereum, Bonk To Become The Shiba Inu Of Solana, Trader Posits</a></li>
</ul>
Image: Shutterstock

$BONK

$DOGE

$SOL

$TRUMP

Bonk Rallies 10% Following Bonk, Dogecoin, Trump Meme Coin ETF Filing

Wall Street analysts rerated Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) as the U.S. kicked in its earnings season last week.
<ul>
<li>Needham analyst Laura Martin reiterated a Buy rating on Amazon and a <a target="_blank" href="https://www.benzinga.com/quote/AMZN/analyst-ratings" rel="noreferrer noopener">$250&nbsp;price target</a>.</li>
<li>BofA Securities analyst Justin Post maintained a Buy rating on Amazon with a price target of $255.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/25/01/42983278/google-stock-boosted-by-ai-growth-cloud-expansion-and-cost-discipline-despite-doj-and-generative-ai-challenges-analyst" target="_blank" rel="noreferrer noopener">Google Stock Boosted By AI Growth, Cloud Expansion, Cost Discipline Despite DOJ And Generative AI Challenges: Analyst</a>
Needham: Martin hosted a panel of prior Amazon employees during the Needham Growth Conference. 
In answer to a question from the audience, the panelists agreed that Amazon CEO Andy Jassy is the right person to lead the company today. Amazon Web Services is both the present (i.e., high margins and high revenue growth rate) and the future (i.e., large language models and generative AI features, tools, and applications), they said.
They also agreed that Amazon&#8217;s strategy is shifting away from e-commerce and toward becoming the backbone of large language models, or LLMs. Jassy was the former founder and president of AWS.
Since Jassy became CEO, he has lowered the amount spent on long-term bets, such as the Fire Phone and Grocery, to improve near-term profitability and reallocate more resources toward AWS.
Amazon has a &#8220;debate and commit&#8221; culture. After everyone voices their disagreements, a decision is reached, and everyone commits. The downside of this culture is that challenging projects and problems never stop. If the old team cannot figure it out, new folks are rotated into that problem. Among all the panelists, they could only think of 2 projects that had ever been shut down. This inability to end risk-taking projects wastes time and resources.
Amazon has a rotational culture in which employees switch roles every 18-24 months. This rotation ensures fresh perspectives on every problem. It also redirects top talent to high-priority and difficult projects, but it risks talent burnout and high turnover rates.
One panelist argued that Amazon&#8217;s Delivery Service Partner (DSP) model, which relies on external contractors, may not be sustainable over time. Low control and high turnover among DSPs make it hard for Amazon to maintain operational excellence in last-mile delivery.
Retail operates on very thin margins, but operating efficiencies bolster its profitability over time.
Investments in automation and &#8220;hands-off-the-wheel&#8221; technology can improve margins in the future.
Ad Business is leading the industry in data collection and tying ad revenue to actual purchases on Amazon. They said it is the best Retail Media Network available today, and Martin agreed.
See Also: <a href="https://www.benzinga.com/news/global/25/01/43109835/small-caps-soar-apple-slips-treasury-yields-fall-on-trump-day-2-whats-driving-markets-tuesday">Small Caps Soar, Apple Slips, Treasury Yields Fall On Trump Day 2: What&#8217;s Driving Markets Tuesday?</a>
BofA Securities: Amazon outperformed the Nasdaq and e-commerce sector in 2024 (+44%, versus 25% for Nasdaq), aided by multiple expansions, with forward-year P/S growing to 3.1 times (versus 2.3 times at the start of 2024).
While AWS growth and Retail margin expectations have increased, Post noted AI-driven Cloud growth remains a top sector opportunity, while Retail Margin expansion can continue to drive outsized profit growth versus peers. Amazon is also relatively well positioned for the impact of US$ appreciation, which aids Cloud margins.
Post noted that the strong AI-demand cycle for AWS will drive upside in 2025. Further, Retail Margin efficiencies drive outsized profit growth for the company.
Amazon is a robotics play, which should drive a multi-year productivity cycle and reduce labor dependence, according to the analyst. The analyst also flagged a ramp in Prime Video ad dollars, further headcount cost savings from mid-level manager cuts, and online retail normalization as additional growth drivers for 2025.
Post slightly lowered his 2025 estimates for recent US$ appreciation. He lowered 2025 International Revenue by $7 billion (~5% of International revenue but just 1% of total), offset by slightly higher AWS margins. For fiscal 2025, Post estimates Revenue and EPS of $700 billion and $6.10, down from $707 billion and $6.13 prior.
Relative to large-cap peers, Post still expects more stable revenue growth in the first half of 2025 (with potential Cloud acceleration) and better margin expansion and noted Amazon as a relatively strong player in AI (Cloud revenues, robotics, R&amp;D efficiencies).
Price Action: Amazon stock is up 2.35% at $231.25 at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence" target="_blank" rel="noreferrer noopener">Microsoft Launches CoreAI Division: Ex-Meta Exec To Supercharge Copilot And AI Innovations</a></li>
</ul>
Image: Shutterstock

AWS, Robotics, Prime Video Ads Fuel Amazon Growth Potential: Analysts

Investors with a lot of money to spend have taken a bullish stance on Nano Nuclear Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NNE, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 17 options trades for Nano Nuclear Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 58% bullish and 23%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $28,700, and 16, calls, for a total amount of $1,189,005.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $35.0 for Nano Nuclear Energy over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Nano Nuclear Energy's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Nano Nuclear Energy's significant trades, within a strike price range of $20.0 to $35.0, over the past month.
<h3>Nano Nuclear Energy Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737487842_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$30.00</td>
<td>$225.0K</td>
<td>16</td>
<td>794</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.4</td>
<td>$2.0</td>
<td>$2.4</td>
<td>$30.00</td>
<td>$118.5K</td>
<td>3.8K</td>
<td>3.4K</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.25</td>
<td>$1.9</td>
<td>$2.25</td>
<td>$30.00</td>
<td>$112.5K</td>
<td>3.8K</td>
<td>2.3K</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.0</td>
<td>$1.95</td>
<td>$2.0</td>
<td>$30.00</td>
<td>$100.0K</td>
<td>3.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.6</td>
<td>$2.35</td>
<td>$2.45</td>
<td>$30.00</td>
<td>$98.0K</td>
<td>3.8K</td>
<td>5.8K</td>
</tr>
</tbody>
</table>

<h3>About Nano Nuclear Energy</h3>
Nano Nuclear Energy Inc is an early-stage nuclear energy company developing smaller, cheaper, and safer portable clean energy solutions. It is focused on four business lines as part of development-Micro Nuclear Reactor Business is developing the next-generation nuclear microreactors, in particular ZEUS, a solid core battery reactor, and ODIN, a low-pressure salt coolant reactor; Fuel Processing Business; Fuel Fabrication Business; Fuel Transportation Business, and Nuclear Consultation Services.
After a thorough review of the options trading surrounding Nano Nuclear Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Nano Nuclear Energy</h3>
<ul>
<li>Currently trading with a volume of 6,123,436, the NNE's price is up by 21.52%, now at $30.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 24 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nano Nuclear Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Nano Nuclear Energy's Options: A Look at What the Big Money is Thinking

High-rolling investors have positioned themselves bullish on Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in BK often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for Bank of New York Mellon. This is not a typical pattern.
The sentiment among these major traders is split, with 30% bullish and 30% bearish. Among all the options we identified, there was one put, amounting to $42,320, and 12 calls, totaling $9,530,843.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $85.0 for Bank of New York Mellon over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Bank of New York Mellon's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Bank of New York Mellon's significant trades, within a strike price range of $55.0 to $85.0, over the past month.
<h3>Bank of New York Mellon Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737487837_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$29.5</td>
<td>$29.2</td>
<td>$29.32</td>
<td>$55.00</td>
<td>$1.5M</td>
<td>3.3K</td>
<td>948</td>
</tr>
<tr>
<td>BK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$31.4</td>
<td>$27.8</td>
<td>$29.34</td>
<td>$55.00</td>
<td>$1.5M</td>
<td>3.3K</td>
<td>3.2K</td>
</tr>
<tr>
<td>BK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$29.4</td>
<td>$29.1</td>
<td>$29.26</td>
<td>$55.00</td>
<td>$1.4M</td>
<td>3.3K</td>
<td>2.2K</td>
</tr>
<tr>
<td>BK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$30.9</td>
<td>$27.8</td>
<td>$29.28</td>
<td>$55.00</td>
<td>$1.3M</td>
<td>3.3K</td>
<td>2.6K</td>
</tr>
<tr>
<td>BK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$29.4</td>
<td>$28.6</td>
<td>$29.26</td>
<td>$55.00</td>
<td>$1.0M</td>
<td>3.3K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>

<h3>About Bank of New York Mellon</h3>
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with $52.1 trillion in under custody or administration (as of September 2024), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.1 trillion in assets.
After a thorough review of the options trading surrounding Bank of New York Mellon, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Bank of New York Mellon's Current Market Status</h3>
<ul>
<li>With a volume of 1,884,543, the price of BK is up 1.48% at $84.52. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bank of New York Mellon options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On Bank of New York Mellon

Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb.
Looking at options history for Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) we detected 26 trades.
If we consider the specifics of each trade, it is accurate to state that 34% of the investors opened trades with bullish expectations and 61% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $407,249 and 17, calls, for a total amount of $1,998,519.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $65.0 for Bristol-Myers Squibb during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Bristol-Myers Squibb's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Bristol-Myers Squibb's significant trades, within a strike price range of $50.0 to $65.0, over the past month.
<h3>Bristol-Myers Squibb Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737487832_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.95</td>
<td>$6.75</td>
<td>$6.85</td>
<td>$55.00</td>
<td>$510.3K</td>
<td>8.7K</td>
<td>801</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$55.00</td>
<td>$360.1K</td>
<td>12.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$55.00</td>
<td>$263.2K</td>
<td>12.3K</td>
<td>1.6K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.55</td>
<td>$6.4</td>
<td>$6.55</td>
<td>$52.50</td>
<td>$149.3K</td>
<td>1.9K</td>
<td>229</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$55.00</td>
<td>$136.8K</td>
<td>12.3K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Bristol-Myers Squibb Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,648,166, with BMY's price up by 1.13%, positioned at $56.92.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 16 days.</li>
</ul>
<h3>Professional Analyst Ratings for Bristol-Myers Squibb</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $65.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Bristol-Myers Squibb, maintaining a target price of $65. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bristol-Myers Squibb options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Bristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment

STERIS shares are trading higher. The company announced outcomes from the ethylene oxide trial.

CHKP

Check Point Software shares are trading higher after Scotiabank raised its price target on the stock from $200 to $215.

DA Davidson analyst Linda Bolton Weiser maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Buy and maintains $170 price target.

DA Davidson Maintains Buy on e.l.f. Beauty, Maintains $170 Price Target

Smurfit WestRock shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and announced a price target of $62.

DA Davidson analyst Linda Bolton Weiser maintains WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) with a Buy and maintains $322 price target.

WDFC

DA Davidson Maintains Buy on WD-40, Maintains $322 Price Target

Amer Sports shares are trading higher after Morgan Stanley raised its price target on the stock from $19 to $27.

Deep-pocketed investors have adopted a bullish approach towards Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LRCX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 35 extraordinary options activities for Lam Research. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 25% bearish. Among these notable options, 16 are puts, totaling $1,579,298, and 19 are calls, amounting to $850,224.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $100.0 for Lam Research, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Lam Research's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Lam Research's whale activity within a strike price range from $70.0 to $100.0 in the last 30 days. 
<h3>Lam Research Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737486987_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$12.3</td>
<td>$11.75</td>
<td>$12.05</td>
<td>$86.00</td>
<td>$389.2K</td>
<td align="right">264</td>
<td align="right">323</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$9.4</td>
<td>$9.3</td>
<td>$9.3</td>
<td>$88.00</td>
<td>$246.4K</td>
<td align="right">656</td>
<td align="right">300</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$23.85</td>
<td>$21.6</td>
<td>$22.35</td>
<td>$98.00</td>
<td>$183.2K</td>
<td align="right">171</td>
<td align="right">82</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.15</td>
<td>$11.05</td>
<td>$11.05</td>
<td>$90.00</td>
<td>$142.5K</td>
<td align="right">714</td>
<td align="right">135</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.0</td>
<td>$10.55</td>
<td>$11.0</td>
<td>$88.00</td>
<td>$104.5K</td>
<td align="right">169</td>
<td align="right">171</td>
</tr>
</tbody>
</table>

<h3>About Lam Research</h3>
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
After a thorough review of the options trading surrounding Lam Research, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Lam Research Standing Right Now?</h3>
<ul>
<li>With a volume of 5,213,585, the price of LRCX is up 2.33% at $82.17. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>What Analysts Are Saying About Lam Research</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $85.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Lam Research with a target price of $75. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Lam Research, which currently sits at a price target of $82. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Lam Research with a target price of $90. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Lam Research, which currently sits at a price target of $85. 
&#x2A; An analyst from Keybanc upgraded its action to Overweight with a price target of $95. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Lam Research, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

LRCX

This Is What Whales Are Betting On Lam Research

Deep-pocketed investors have adopted a bullish approach towards Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Blackstone. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 40% leaning bullish and 40% bearish. Among these notable options, 10 are puts, totaling $630,808, and 12 are calls, amounting to $654,163.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $105.0 to $210.0 for Blackstone during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Blackstone stands at 870.71, with a total volume reaching 4,161.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Blackstone, situated within the strike price corridor from $105.0 to $210.0, throughout the last 30 days.
<h3>Blackstone Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737486982_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$4.15</td>
<td>$1.92</td>
<td>$3.95</td>
<td>$105.00</td>
<td>$158.0K</td>
<td align="right">124</td>
<td align="right">400</td>
</tr>
<tr>
<td>BX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$14.7</td>
<td>$14.65</td>
<td>$14.7</td>
<td>$170.00</td>
<td>$149.9K</td>
<td align="right">767</td>
<td align="right">102</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$4.45</td>
<td>$3.5</td>
<td>$3.82</td>
<td>$185.00</td>
<td>$114.2K</td>
<td align="right">60</td>
<td align="right">300</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$7.65</td>
<td>$7.2</td>
<td>$7.5</td>
<td>$175.00</td>
<td>$93.7K</td>
<td align="right">481</td>
<td align="right">139</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$7.55</td>
<td>$7.4</td>
<td>$7.5</td>
<td>$175.00</td>
<td>$88.5K</td>
<td align="right">481</td>
<td align="right">264</td>
</tr>
</tbody>
</table>

<h3>About Blackstone</h3>
Blackstone is the world's largest alternative-asset manager with $1.108 trillion in total asset under management, including $820.5 billion in fee-earning assets under management, at the end of September 2024. The company has four core business segments: private equity (25% of fee-earning AUM and 30% of base management fees), real estate (35% and 39%), credit and insurance (31% and 24%), and multi-asset investing (9% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
Following our analysis of the options activities associated with Blackstone, we pivot to a closer look at the company's own performance.
<h3>Where Is Blackstone Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,366,334, the BX's price is up by 0.89%, now at $181.56. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 9 days.</li>
</ul>
<h3>What The Experts Say On Blackstone</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $181.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Keefe, Bruyette &amp; Woods keeps a Market Perform rating on Blackstone with a target price of $174. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Blackstone, which currently sits at a price target of $192. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Blackstone with a target price of $180. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Blackstone, maintaining a target price of $179. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Blackstone options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Blackstone

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inozyme Pharma (INZY – Research Report) and Intellia...

Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) on January 10 and set a price targ...

Intellia Therapeutics' Strategic Reorganization and Promising Clinical Progress Justify Buy Rating

Oppenheimer lowered the firm's price target on Intellia Therapeutics (NTLA) to $40 from $60 and keeps an Outperform rating on the shares after mana...

Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer

Intellia Therapeutics: Buying The Path To Commercialization

After having hosted Intellia Therapeutics (NTLA)' CEO John Leonard at the firm's healthcare conference, JPMorgan said management "shed light" on th...

Intellia ATTR, HAE studies progressing as planned, says JPMorgan

J.P. Morgan analyst Brian Cheng has maintained their bullish stance on NTLA stock, giving a Buy rating today. Brian Cheng has given his Buy rating ...

Intellia Therapeutics: Strategic Initiatives and Clinical Progress Justify Buy Rating

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report...

Intellia Therapeutics (NTLA) Receives a Buy from Bank of America Securities

Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade)

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

EDIT

INZY

VRTX

Press Releases

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

General

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Ardelyx

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Avid Bioservices

CareDx

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

89bio

Gyre Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

Myriad Genetics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Relay Therapeutics

Sana Biotechnology

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Tyra Biosciences

Zymeworks

Goldman Sachs

Oppenheimer

Wells Fargo

BMO Capital

Canaccord Genuity

캐시 우드가 이끄는 아크 인베스트는 금요일에 리커젼 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 클라우드플레어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) 그리고 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)의 주요 회사들에서 상당한 거래를 진행했다.
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div class="sc-hZlppA ddOBfh get-report-button flex">
<div></div>
</div>
</div>
</div>
RXRX 거래
아크 인베스트(Ark Invest)의 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)가 리커젼 파마슈티컬스의 주식 264,596주를 대량으로 매수했다.
이 거래의 가치는 종가인 6.88달러를 기준으로 약 1.82 백만 달러이다. 이 결정은 금요일에 RXRX의 주가가 5.23% 하락한 것에도 불구하고 이루어졌다.
ILMN 거래
아크 인베스트의 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 ARK Innovation ETF가 일루미나의 주식을 매수했다.
ARKG는 4,038주를 매수했고, ARKK는 11,425주를 매수했다. 이 거래들의 총 가치는 종가인 136.69달러를 기준으로 약 1.97 백만 달러이다.
이 결정은 일루미나의 주가가 금요일에 2.14% 하락한 것에도 불구하고 이루어졌다.
참고: <a href="https://www.benzinga.com/25/01/42931747/bitcoin-supercycle-incoming-says-economist-but-theres-a-catch">비트코인 슈퍼사이클이 온다, 경제학자가 말하지만, 함정이 있다</a>
NTLA 거래
아크 인베스트의 Genomic Revolution ETF와 ARK Innovation ETF가 인텔리아 테라퓨틱스의 주식을 매수했다.
ARKG는 41,503주를 매수했고, ARKK는 124,799주를 매수했다.
이 거래들의 총 가치는 종가인 10.2달러를 기준으로 약 1.46 백만 달러이다. 이 결정은 NTLA의 주가가 금요일에 15.14% 하락한 것에도 불구하고 이루어졌다.
인텔리아 테라퓨틱스는 금요일에 비용 절감을 위해 27%의 인력 감축을 발표했다.
NET 거래
아크 인베스트의 Next Generation Internet ETF(ARKW)가 클라우드플레어의 주식 7,840주를 매도했다.
이 거래의 가치는 종가인 112.62달러를 기준으로 약 882,608달러이다. 이 결정은 NET의 주가가 금요일에 2.66% 하락한 것에도 불구하고 이루어졌다.
ADPT 거래
아크 인베스트의 Genomic Revolution ETF가 어댑티브 바이오테크놀로지스의 주식 130,790주를 매도했다.
이 거래의 가치는 종가인 6.5달러를 기준으로 약 850,135달러이다. 이 결정은 ADPT의 주가가 금요일에 2.84% 하락한 것에도 불구하고 이루어졌다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-">마크 저커버그가 &#8216;문화적으로 무력화된&#8217; 기업들을 비판하고, 메타가 DEI 프로그램을 중단하자 &#8216;남성 에너지&#8217;를 옹호하다</a></li>
</ul>
면책조항: 이 콘텐츠는 AI 도구의 도움으로 부분적으로 생성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
사진 제공: Ark Invest


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.
무슨 일 있었나: 캐시 우드의 열정은 의료와 신약 개발에 혁명을 일으킬 수 있는 혁신적인 기술 융합에 집중되어 있다.
그는 이 분야에 대해 솔직하게 이야기하면서 특히 크리스퍼 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) 같은 회사에서 유전자 치료의 괄목할 만한 발전이 이루어지고 있다고 강조했다.
가장 눈에 띄는 사례는 최근 크리스퍼 테라퓨틱스가 겸상 적혈구 질환 치료 분야에서 거둔 획기적인 성과다. 우드는 이전에는 연간 12~20회 수혈을 받아야 했던 환자들이 이제 그런 수혈을 받지 않아도 될 수 있게 되었다고 언급했다.
이러한 전략은 치료의 혁신을 넘어 신약 개발 자체로 확장횐다. 우드는 리커션 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)와 같은 회사가 인공지능을 활용하여 임상시험 실패율을 획기적으로 줄이고 신약 개발 일정을 앞당기고 있다고 강조했다.
그러나 이러한 혁신적인 기업들의 시장 성과는 좀 더 복잡한 이야기를 담고 있다. 올해 들어 이들 주식은 상당한 변동성을 보였다. <a href="//www.benzinga.com/pro/"" target="_blank" rel="noopener">벤징가 프로 데이터</a>에 따르면 연초 대비 크리스퍼 테라퓨틱스는 25.36% 하락, 인텔리아 테라퓨틱스는 52.21% 하락, 빔 테라퓨틱스는 3.04% 하락, 리커션 제약은 9.80% 하락했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space.
Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C%EC%9D%98-%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-%ED%85%8C%EC%8A%AC%EB%9D%BC-%EC%A3%BC%EC%8B%9D-1800%EB%A7%8C-%EB%8B%AC%EB%9F%AC-%EC%83%81/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트, 테슬라 주식 1,800만 달러 상당 매각</a>
왜 중요한가: 바이오 분야에 대한 아크 인베스트의 노력은 11억 7,900만 달러의 순자산을 관리하는 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 분명하게 드러난다. 이 펀드의 성과는 2020년 최고 180.50%에서 2022년 최저 -53.94%에 이르는 연간 수익률로 해당 섹터의 변동성을 반영하고 있다.
이 ETF의 현재 상위 보유 종목은 혁신적인 바이오 기술에 대한 캐시 우드의 전략적 초점을 강조한다. 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>)가 8.90%의 비중으로 포트폴리오를 이끌고 있으며, 크리스퍼 테라퓨틱스가 7.88%, 리커션 파마슈티컬스가 6.17%로 그 뒤를 잇고 있다. 그 밖의 주요 투자 기업으로는 케어DX(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등이 있으며, 이들은 게놈 및 생물학적 혁신에 대한 다양한 접근 방식을 대표한다.
캐시 우드는 AI, 시퀀싱 기술, 유전자 편집의 전례 없는 융합 덕분에 향후 5년 동안 바이오 분야에서 4,000억 달러의 시장 기회가 있을 것으로 전망한다.
이미지 출처: Ark Invest
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토 후 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 주식 시장은 목요일에 혼조세를 보였다. 나스닥 종합지수는 130포인트 이상 상승한 반면, 다우존스 지수는 0.3% 하락하여 42,374.36으로 마감되었다. S&amp;P 500 지수도 0.2% 상승하여 5,809.86으로 마감했다.
이날 소매 거래자와 투자자들의 주목을 받은 주요 주식은 다음과 같다:
모노파 테라퓨틱스 (MNPR)
모노파 테라퓨틱스의 주식은 605.40% 급등하여 $32.66에 마감하였으며, 장중 최고가는 $38.5, 최저가는 $4.87였다. 이 회사의 52주 최고가와 최저가는 각각 $38.5와 $1.37이다. 이 회사의 주가는 아스트라제네카(AstraZeneca Plc)의 알렉시온(Alexion)과의 윌슨병 치료제 ALXN-1840에 대한 <a href="https://www.benzinga.com/general/biotech/24/10/41525741/monopar-therapeutics-stock-jumps-4x-inks-licensing-pact-with-astrazeneca-for-once-terminated-phas">독점 전세계 라이선스 계약</a>에 합의한 후 급등했다.
인텔리아 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)
인텔리아 테라퓨틱스의 주가는 20.51% 하락하여 $15.85로 마감했다. 장중 최고가는 $17.74, 최저가는 $15.35였다. 이 회사의 52주 최고가와 최저가는 각각 $34.87와 $15.35이다. 주가는 <a href="https://www.benzinga.com/general/biotech/24/10/41524915/why-is-gene-therapy-focused-intellia-therapeutics-stock-trading-lower-on-thursday">유전자 치료제 NTLA-2002의 2단계 데이터 발표</a> 이후 하락했다.
참고: <a href="https://www.benzinga.com/markets/equities/24/10/41507504/elon-musk-shuts-down-traditional-tesla-25k-ev-rumors-calls-it-pointless-as-company-focuses-on-al?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">일론 머스크, 전통적인 테슬라 2만 5천 달러 EV 루머를 &#8216;무의미하다&#8217;고 일축하며 자율주행 미래에 집중한다고 밝혀</a>
카프리 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>)
카프리 홀딩스의 주가는 0.50% 하락하여 $41.60에 마감했다. 장중 최고가는 $42.21, 최저가는 $41.46였다. 이 회사의 52주 최고가와 최저가는 각각 $51.73와 $29.28이다. 주가는 태피스트리(Tapestry Inc.)와의 합병이 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%B9%B4%ED%94%84%EB%A6%AC%EC%9D%98-%EC%A3%BC%EC%8B%9D%EC%9D%80-%ED%85%8C%ED%94%BC%EC%8A%A4%ED%8A%B8%EB%A6%AC%EC%99%80%EC%9D%98-%ED%95%A9%EB%B3%91%EC%9D%B4-%EC%B0%A8%EB%8B%A8%EB%90%98%EC%9E%90-45/" target="_blank" rel="noopener">법원에 의해 차단되었다는 보도</a> 이후 급락했다.
웨스턴 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)
웨스턴 디지털의 주가는 0.44% 하락하여 $66.32로 마감했다. 장중 최고가는 $67.54, 최저가는 $66.20였다. 52주 최고가와 최저가는 각각 $81.55와 $35.62이다. 이 회사는 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9B%A8%EC%8A%A4%ED%84%B4-%EB%94%94%EC%A7%80%ED%84%B8%EC%9D%98-%EC%A3%BC%EA%B0%80%EB%8A%94-1%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81-%EB%B0%9C%ED%91%9C-%ED%9B%84-%EC%8B%9C%EA%B0%84%EC%99%B8-%EA%B1%B0/" target="_blank" rel="noopener">1분기 실적 발표</a>에서 분석가 예상치를 상회하는 시적을 발표한 후 주가가 상승했다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주가는 21.92% 상승하여 $260.48에 마감했다. 장중 최고가는 $262.12, 최저가는 $242.65였다. 52주 최고가와 최저가는 각각 $271와 $138.8이다. 주요 월가 애널리스트들이 <a href="https://www.benzinga.com/news/24/10/41515376/tesla-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-thursday">여러 회사에 대한 전망을 업데이트</a>했다. 베어드(Baird)는 서비스나우(ServiceNow)의 목표 주가를 올리고, 키뱅크(Keybanc)는 로켓 랩(Rocket Lab)의 목표 주가를 상향 조정했다. 한편, 파이퍼 샌들러(Piper Sandler)는 시높시스(Synopsys)의 목표 주가를 하향 조정하고, HC 웨인라이트는 DBV 테크놀로지스의 전망을 상향 조정했다. JP 모건은 넥스테라 에너지(NextEra Energy)를 상승 등급으로 조정하고, BMO 캐피털은 코스타 그룹(CoStar Group)의 목표 주가를 하향 조정했다.
이미지 출처: Shutterstock
벤징가와 함께 <a href="Premarket Movers &amp; News">상위 프리마켓 동향 및 뉴스</a>를 확인하시고 하루의 거래를 준비하세요.
다음 기사 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41490763/in-legal-weed-state-woman-faces-30-year-sentence-over-bong-water-aclu-steps-in?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">합법적인 대마초 주에서 한 여성이 대마초 물로 30년 형에 처해질 위기에 처하다: ACLU가 개입하다</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.
테슬라 주식
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 테슬라 지분을 줄여 13,213주를 매각했다. 이번 거래는 테슬라의 주가가 최근 화요일에 10.20% 급등해 4월 말 이후 최고의 장중 거래를 기록했다는 점을 감안하면 놀라운 일이었다. 특히 화요일에 아크 인베스트는 <a href="https://www.benzinga.com/markets/equities/24/07/39611275/cathie-woods-ark-invest-sells-tesla-shares-worth-14-5m-amid-rally-driven-by-q2-delivery-numbers-">1,450만 달러</a> 상당의 테슬라 주식을 매각했다.
이러한 상승은 주로 일론 머스크가 이끄는 이 회사의 <a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">2분기 실적</a>에 의해 주도되었다. 테슬라는 예상 차량 439,000대를 크게 초과하는 443,956대를 인도했다고 보고했다. 이러한 놀라운 상승세는 랠리를 촉진하여 주가를 2024년 최고치로 끌어올렸다. 판매의 대부분은 저렴한 모델 3 및 Y에서 이루어졌으며, 더 비싼 모델 X, S 및 신형 사이버트럭에서는 21,551대만 판매되었다.
최종 종가 246.39달러를 기준으로 수요일에 판매된 주식의 가치는 약 325만 달러에 달한다. 이날 테슬라 주가는 6.5% 급등했다.
기타 중요한 거래:
<ul>
<li>아크 인베스트의 ARKF 펀드는 텔레닥(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 팔았다.</li>
<li>ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 2,551주 매수하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 주를 팔았다.</li>
<li>ARKK 펀드는 아처 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>)의 주를 사고, 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주를 팔았다.</li>
<li>ARKQ 펀드는 에어로바이런먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)의 주를 팔았다. ARKX 펀드는 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)의 주를 샀다.</li>
</ul>
이미지는 셧터스톡을 통해 제공됨
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했다

ACHR

AVAV

BLDE

TDOC

VERV

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)와 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래
ARK 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 로쿠에서 127,540주를 매입했다. ARKK 펀드는 106,420주를 인수했고, ARKW 펀드는 21,120주를 추가했다. 이 거래액은 730만 달러에 달했다. 수요일, 로쿠의 주가는 정기 세션에서 4.6% 상승한 57.16달러로 마감했다.
특히 우드의 회사는 <a href="https://www.benzinga.com/markets/equities/24/06/39493817/cathie-wood-led-ark-invest-dumps-4-3m-worth-of-nvidia-shares-amid-rebound-swoops-into-buy-stock-">하루 전</a>에 530만 달러 상당의 로쿠 주식을 구매했다. 이러한 움직임은 <a href="https://www.benzinga.com/general/entertainment/24/06/39422115/roku-stocks-wild-ride-bullish-analysts-bet-on-growth-despite-competitive-threats" target="_blank" rel="noopener">치열한 강세와 약세 논쟁</a> 사이에 주식이 갇힌 로쿠의 격동적인 시장 움직임 속에서 이루어졌다.
TV 스트리밍 플랫폼이자 넷플릭스와 같은 스트리밍 플랫폼의 경쟁사인 로쿠는 <a href="https://www.benzinga.com/markets/equities/24/06/39295418/whats-going-on-with-tv-streaming-platform-rokus-shares-on-wednesday">최근</a> 광고 인벤토리와 광고주 수요를 직접 연결하는 광고 기술 솔루션인 로쿠 익스체인지(Roku Exchange)를 출시했다.
코인베이스 거래
아크 인베스트의 ARKW ETF는 703,393달러 상당의 코인베이스 주식 3,278주를 매각했다. 이번 판매는 미국 정부와 연결되어 있는 것으로 여겨지는 지갑을 통해 상당한 규모의 암호화폐가 코인베이스로 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39511595/uncle-sam-on-the-move-us-government-transfers-millions-in-bitcoin-to-coinbase" target="_blank" rel="noopener">이전</a>된 데 따른 것이다. 미국 정부는 2억 4,100만 달러 상당의 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ​​3,940개를 코인베이스로 이전했다.
미국 정부의 이러한 움직임으로 인해 암호화폐 시장이 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39516076/bitcoin-ethereum-dogecoin-retrace-on-fears-of-240m-sale-by-us-government-king-crypto-shoul">하락</a>했다. 비트코인은 이전 거래 세션에서 62,000달러로 약간 반등한 후 61,000달러 아래로 떨어졌다.
그 외 핵심 거래들:
<ul>
<li>아크 인베스트의 ARKG ETF는 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주식을 팔고 10X 지노믹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>)의 주식을 샀다.</li>
<li>ARKG 펀드는 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 매도하고 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 샀다.</li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>가 작성하고 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집한 바 있다.

$BTC

ARKW

COIN

ROKU

아크 인베스트는 로쿠 $730만의 주식을 매수, 비트코인 하락에 코인베이스 주식을 매각

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:
로빈후드에서 포지션을 축소하기로 한 아크 인베스트의 결정은 세 가지 ETF를 통해 실행되었다. ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 31,827주를 매각했고, ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 215,675주와 76,299주를 매각했다. 월요일 로빈후드의 종가 23.42달러를 기준으로 판매된 주식의 총 가치는 약 760만 달러이다.
로빈후드 주식의 변동성은 <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock" target="_blank" rel="noopener">밈 주식 열기가 부활</a>하는 가운데 발생했다. 최근 로빈후드의 CEO 블래디미어 테네브는 게임스탑에 투자한 것으로 유명한 로어링 키티(Roaring Kitty)이라고도 알려진 키스 길(Keith Gill)의 예정된 라이브 스트리밍으로 인한 트래픽 유입을 회사가 처리할 준비가 되었다고 발표했다. 이 회사는 또한 최근 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">10억 달러 규모의 자사주 매입</a>을 발표했는데, 이는 주가 상승 추세에 기여했다.
특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 등 주요 코인들이 적자로 거래되면서 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-" target="_blank" rel="noopener">고르지 못한 암호화폐 시장</a>을 배경으로 거래가 성사됐다.
다른 중요한 거래:
<ul>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): ARKG 및 ARKK를 통해 주식 매도.</li>
<li>아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): ARKG를 통해 주식 매입.</li>
<li>텔라닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG를 통해 주식 매도.</li>
<li>인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): ARKG 및 ARKK를 통해 주식 매입.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG 및 ARKK를 통해 주식 매도. 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): ARKG 및 ARKK를 통해 5,804주 매입.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CEO 일자리 대안에 대한 투자자의 협상</a>
이 이야기는 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>의 편집을 거쳐 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었습니다.

$ETH

ARCT

ARKF

EXAS

HOOD

아크 인베스트가 게임스톱 관련 뉴스와 비트코인 변동성 속에서 로빈후드 주식 $7.6백만 매각

목요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)과 레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>)에서 상당한 거래를 성사시켰으며 두 회사 모두 눈에 띄는 움직임을 보였다.
아마존닷컴 거래:
아크 인베스트의 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 아마존 주식 53,368주를 매입했다. 이러한 움직임은 Amazon이 최근 760억 달러 규모의 11년 계약의 일환으로 NBA 미디어 권리를 <a href="https://www.benzinga.com/general/sports/24/06/39215473/amazon-makes-prime-bet-on-sports-with-nba-deal-streaming-platform-will-have-content-from-4-major-l">인수</a>한 이후에 나온 것이다. 이러한 전략적 움직임은 아마존 프라임 비디오(Amazon Prime Video) 스트리밍 플랫폼의 가입자 수를 늘릴 것으로 예상된다. 목요일 아마존의 종가 185달러를 기준으로 한 이번 거래 가치는 약 990만 달러이다.
레딧 거래:
별도의 거래에서, 아크 인베스트의 Ark 핀테크 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 레딧 주식 1,312주를 매입했다. 이번 매입은 레딧이 최근 고객 경험 관리 플랫폼 기업 스프링클(Sprinklr)과의 <a href="https://www.benzinga.com/news/24/06/39208968/whats-going-on-with-reddit-stock-today">확대된 파트너십 발표한</a> 것과 일치한다. 이 파트너십을 통해 스프링클 고객들은 레딧의 전체 광고 제품군에 액세스하고 레딧을 기업 광고 전략에 통합할 수 있다. 레딧의 목요일 종가 63.46달러를 기준으로 한 이 거래의 가치는 약 83,200달러이다.
다른 중요한 거래:
<ul>
<li>아크 인베스의 ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) 주식 25,736주를 매입하고, 이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)의 12,602주를 팔았다.</li>
<li>ARKK 펀드는 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>)의 106,192주를 매입하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 126,699주를 팔았다. ARKW 펀드는 서비스나우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)의 14,121주를 매도했다.</li>
</ul>
다른 중요한 거래를 읽어보세요: <a href="https://www.benzinga.com/markets/equities/24/06/39192292/amc-stock-rises-as-annual-shareholder-meeting-results-roll-in-whats-going-on?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AMC주가 상승, 연례 주주총회 결과 발표: 무슨 일이?</a>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 작성되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.

Comments

Intellia Therapeutics

뉴스

에 대한 최신 뉴스 Intellia Therapeutics (NASDAQ:NTLA) 주식

일요일, 1월 12, 2025

수요일, 11월 27, 2024

금요일, 10월 25, 2024

목요일, 7월 04, 2024

목요일, 6월 27, 2024

화요일, 6월 11, 2024

금요일, 6월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌